Sprint Bioscience AB
STO:SPRINT
Balance Sheet
Balance Sheet Decomposition
Sprint Bioscience AB
Sprint Bioscience AB
Balance Sheet
Sprint Bioscience AB
| Dec-2012 | Dec-2013 | Dec-2014 | Dec-2015 | Dec-2016 | Dec-2017 | Dec-2018 | Dec-2019 | Dec-2020 | Dec-2021 | Dec-2022 | Dec-2023 | Dec-2024 | Dec-2025 | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||||
| Cash & Cash Equivalents |
0
|
1
|
14
|
8
|
24
|
1
|
15
|
8
|
27
|
71
|
29
|
50
|
25
|
127
|
|
| Cash |
0
|
0
|
0
|
0
|
0
|
0
|
15
|
8
|
27
|
71
|
29
|
50
|
25
|
127
|
|
| Cash Equivalents |
0
|
1
|
14
|
8
|
24
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Receivables |
2
|
0
|
1
|
0
|
2
|
2
|
2
|
7
|
3
|
5
|
5
|
8
|
12
|
6
|
|
| Accounts Receivables |
1
|
0
|
0
|
0
|
2
|
2
|
2
|
7
|
3
|
0
|
0
|
0
|
0
|
0
|
|
| Other Receivables |
1
|
0
|
1
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Inventory |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Assets |
0
|
0
|
0
|
0
|
1
|
1
|
2
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
|
| Total Current Assets |
2
|
1
|
15
|
0
|
27
|
5
|
18
|
17
|
32
|
76
|
35
|
58
|
37
|
133
|
|
| PP&E Net |
0
|
1
|
1
|
0
|
2
|
2
|
2
|
2
|
1
|
3
|
2
|
4
|
5
|
4
|
|
| PP&E Gross |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
2
|
1
|
0
|
0
|
0
|
0
|
0
|
|
| Accumulated Depreciation |
0
|
0
|
0
|
0
|
0
|
0
|
2
|
3
|
4
|
0
|
0
|
0
|
0
|
0
|
|
| Intangible Assets |
2
|
6
|
10
|
15
|
21
|
29
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Note Receivable |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Long-Term Investments |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Long-Term Assets |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Assets |
4
N/A
|
7
+74%
|
25
+237%
|
0
N/A
|
50
N/A
|
35
-28%
|
21
-42%
|
19
-6%
|
33
+74%
|
79
+137%
|
37
-53%
|
62
+67%
|
42
-33%
|
137
+225%
|
|
| Liabilities | |||||||||||||||
| Accounts Payable |
1
|
1
|
1
|
0
|
4
|
3
|
5
|
3
|
3
|
3
|
4
|
6
|
5
|
4
|
|
| Accrued Liabilities |
0
|
1
|
1
|
0
|
16
|
3
|
5
|
6
|
10
|
0
|
0
|
0
|
0
|
0
|
|
| Short-Term Debt |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
10
|
0
|
0
|
0
|
0
|
0
|
|
| Current Portion of Long-Term Debt |
0
|
0
|
1
|
0
|
1
|
0
|
12
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Current Liabilities |
2
|
0
|
0
|
1
|
1
|
1
|
0
|
0
|
1
|
6
|
6
|
29
|
27
|
13
|
|
| Total Current Liabilities |
3
|
2
|
3
|
1
|
21
|
7
|
22
|
8
|
24
|
9
|
9
|
35
|
33
|
17
|
|
| Long-Term Debt |
1
|
2
|
2
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Other Liabilities |
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Liabilities |
3
N/A
|
4
+28%
|
5
+18%
|
0
N/A
|
21
N/A
|
7
-65%
|
22
+198%
|
8
-63%
|
24
+195%
|
9
-64%
|
9
+6%
|
35
+275%
|
33
-5%
|
17
-47%
|
|
| Equity | |||||||||||||||
| Common Stock |
0
|
0
|
0
|
0
|
1
|
1
|
1
|
1
|
2
|
4
|
7
|
7
|
7
|
7
|
|
| Retained Earnings |
0
|
0
|
0
|
0
|
40
|
59
|
103
|
125
|
167
|
192
|
253
|
253
|
271
|
180
|
|
| Additional Paid In Capital |
0
|
0
|
0
|
0
|
59
|
69
|
101
|
134
|
174
|
259
|
274
|
274
|
274
|
292
|
|
| Other Equity |
1
|
3
|
20
|
0
|
9
|
17
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
0
|
|
| Total Equity |
1
N/A
|
3
+205%
|
20
+505%
|
0
N/A
|
28
N/A
|
28
-1%
|
2
N/A
|
11
N/A
|
9
-17%
|
70
+670%
|
28
-60%
|
28
-1%
|
9
-67%
|
119
+1 185%
|
|
| Total Liabilities & Equity |
4
N/A
|
7
+74%
|
25
+237%
|
0
N/A
|
50
N/A
|
35
-28%
|
21
-42%
|
19
-6%
|
33
+74%
|
79
+137%
|
37
-53%
|
62
+67%
|
42
-33%
|
137
+225%
|
|
| Shares Outstanding | |||||||||||||||
| Common Shares Outstanding |
7
|
7
|
7
|
0
|
9
|
10
|
14
|
17
|
26
|
47
|
71
|
71
|
71
|
106
|
|